CD82抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of NIH/3T3 cells using CD82 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CD82 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CD82 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human lymph tissues using CD82 mouse mAb with DAB staining.    

  
  

CD82 antibody targets the CD82 protein, a member of the tetraspanin family, which plays a critical role in regulating cell signaling, adhesion, and motility. Initially identified as a tumor suppressor, CD82 (also known as KAI1) is implicated in inhibiting cancer metastasis by modulating integrin-dependent pathways and suppressing epithelial-mesenchymal transition (EMT). Its reduced expression correlates with poor prognosis in various cancers, including prostate, breast, and lung cancers. CD82 also interacts with other tetraspanins and membrane proteins to form dynamic "tetraspanin-enriched microdomains," influencing immune responses, viral infection (e.g., HIV-1 entry), and cell fusion processes.

Antibodies against CD82 are widely used in research to study its expression patterns, functional mechanisms, and interactions in both normal and pathological contexts. They enable detection via techniques like flow cytometry, immunohistochemistry, and Western blotting. Therapeutic exploration of CD82 antibodies focuses on restoring its expression or activity to impede metastatic progression. However, challenges remain in understanding context-dependent roles, as CD82 may exhibit dual functions in different cancers or stages. Ongoing studies aim to clarify its regulatory networks and potential as a diagnostic biomarker or therapeutic target in oncology and infectious diseases.